Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

NewAmsterdam Pharma (NAMS) Operating Expenses (2022 - 2025)

Historic Operating Expenses for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $55.5 million.

  • NewAmsterdam Pharma's Operating Expenses rose 254.46% to $55.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.2 million, marking a year-over-year increase of 939.11%. This contributed to the annual value of $221.9 million for FY2024, which is 1258.27% up from last year.
  • Per NewAmsterdam Pharma's latest filing, its Operating Expenses stood at $55.5 million for Q3 2025, which was up 254.46% from $54.8 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Operating Expenses' 5-year high stood at $71.9 million during Q1 2025, with a 5-year trough of $44.2 million in Q2 2023.
  • Moreover, its 3-year median value for Operating Expenses was $54.8 million (2025), whereas its average is $54.6 million.
  • Examining YoY changes over the last 5 years, NewAmsterdam Pharma's Operating Expenses showed a top increase of 2640.51% in 2025 and a maximum decrease of 13.49% in 2025.
  • Quarter analysis of 3 years shows NewAmsterdam Pharma's Operating Expenses stood at $51.9 million in 2023, then rose by 7.95% to $56.0 million in 2024, then decreased by 0.91% to $55.5 million in 2025.
  • Its Operating Expenses was $55.5 million in Q3 2025, compared to $54.8 million in Q2 2025 and $71.9 million in Q1 2025.